

**One of the Most Deadly Ailments
Known to Western Culture is about
to be Wiped Out for Good**

**This Small Company Could Steal
\$14.5 Billion of Sales From Drug
Giants Pfizer and Merck ...**

**...And Make You 465%
in the next 6 Months!**

Dear Reader,

The following quote, taken from *The New York Times*, tells you exactly where to put your money today:

"In the not too distant future, the top 20 companies in pharmaceuticals, with the exception of one or two, would be unfamiliar names."

- Nathan Myhrvold, former top scientist at Microsoft Corporation)

Mr. Myhrvold is one smart cookie...

He earned his master's degree in geophysics and space physics at age 19. He co-authored the book *The Road Ahead* with Bill Gates. *Time* Magazine ranked him 9th in their "Cyber Elite Top 50," ahead of Michael Dell, Paul Allen, Jeff Bezos, Rupert Murdoch and John Chambers.

"Vantage Point Investment Advisory is great and James Dale Davidson's point of view is exceptional. I always enjoy the newsletter and am excited to read about the investments that you are looking at. Thank you for the opportunity to learn. I expect to be a subscriber for some time."

Art Runningbear, VPI reader

I don't know Mr. Myhrvold. I've never met him in my life. But his credentials speak for themselves. The point is, he knows what he's talking about. So it's big news when he says companies like Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer and Schering-Plough (which account for \$685 billion in market caps) could soon be all but forgotten.

In fact, it's already starting to happen. Over the last five months, the top 20 pharmaceutical companies have lost an average of 15%...worth \$102 billion in market cap.

The reason Myhrvold believes that 90% of today's major pharmaceutical companies are falling -- and will continue to fall -- is because of innovative companies like the one you'll learn about today.

Imaginative researchers at this company didn't throttle back to a conservative idle just because the Nasdaq was down the last three years.

While Big Pharma devotes most of its time chiseling away at cost

structures and employee payrolls, this innovative company (with less than 100 employees) could launch a new drug that represents one of the biggest advances in health care in the past 20 years.

For reasons detailed in this letter, you'll see why this \$14 stock could soon, in my opinion, make Pfizer's Lipitor and Merck's ZOCOR (two of the most profitable drugs in America that stand to generate \$14.5 billion in combined sales this year) ***all but worthless***.

There is only a brief window, perhaps just weeks, before these shares take off. Act today, and you could make 465% over the next six months *with or without FDA approval!*

\$1 Billion in Revenues Overnight

Right now, this company has a drug in Phase III of FDA trials that addresses atherosclerosis, a disease resulting from inflammation and build-up of plaque under the inner lining of arteries.

Risk factors associated with atherosclerosis include high cholesterol, high blood pressure, smoking, type 1 diabetes, obesity and physical inactivity. Forgive me if this sounds insensitive, but that pretty much characterizes 85% of Americans today.

The market is massive and growing larger by the day.

The most serious consequence of atherosclerosis is coronary heart disease (CHD). According to the American Heart Association, over 14 million Americans suffer from CHD and its leading form, coronary artery disease (CAD). I bet you're not aware of this, but CHD is the leading cause of death in Western societies, claiming more lives each year than

all forms of cancer...**combined**.

The estimated cost of CHD in the United States in 2001 was \$100.8 billion in direct and indirect costs. That same year, CHD caused 700,142 deaths in the United States...1 out of every 3 deaths.

In fact, up to 50% of all deaths in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are attributable to heart disease. That's why Pfizer's Lipitor and Merck's ZOCOR stand to gross \$14.5 billion in sales this year.

Now, here's where it gets interesting...

Lipitor and ZOCOR are profiting off the notion that heart attacks are caused solely by high cholesterol.

But guess what? Half of all heart disease patients don't even have high cholesterol.

This fact dispels the myth that heart attacks are caused only by cholesterol clogging up the body's plumbing like grease in pipes. Heart attacks can also be caused by diabetes, high blood pressure or the chemicals in cigarette smoke.

Although Lipitor and ZOCOR cut down on deaths from heart attacks and strokes by lowering blood cholesterol, that's not good enough. Doctors know it. Patients know it. And you better believe Big Pharma knows it.

The truth is...

While lowering cholesterol helps, it only partially heads off the real danger -- your body's own inflammatory response. But today, there's no

alternative treatment.

At least not yet...

You see, an artery can swell in response to any one of the risk factors listed above -- high cholesterol, high blood pressure, smoking, type 1 diabetes, obesity and physical inactivity.

Swelling of vessel walls causes cholesterol plaques to rupture. When this happens, a clot forms around the lesion, creating a blockage that starves the heart of oxygen, which kills part of it. This leads to inflammation of blood vessels, which, in turn, cause heart attacks.

As it stands today, Lipitor and ZOCOR can't prevent heart attacks by any other means than lowering cholesterol. There are no medications available for physicians to directly treat atherosclerosis.

That's why investing in this tiny company today could make you rich.

Quadruple Your Money Just off the "Buzz"

This company has a pill that promises to reduce artery swelling, which could save the 700,142 lives that Lipitor and ZOCOR can't. And after 13 years of work, this company's experimental drug has made it into late-stage clinical trials.

Last summer, this company began a \$40 million, 4,000-patient trial to see if taking the pill in addition to existing drugs could

"I like the approach you take and the companies you follow. It's refreshing being out of the mainstream stocks with their massive float. Knock on wood - the investments I've made with your picks are beyond what I had hoped for."

J.P., VPI reader

reduce death and hospitalizations from heart attacks, strokes and other cardiovascular problems in people who have already had heart attacks.

Although there are no sure things, high-ranking cardiologists give the drug a pretty good chance. But quite honestly, that doesn't even matter.

Here's the real reason why this stock is a winner...

Since this announcement will be one of the most heavily-documented FDA decisions next year, it's only a matter of time before national media catches on to what's happening...and turns this unknown company into a household name.

When the public finally understands what you've just learned (that this company can steal \$14.5 billion in sales from Pfizer and Merck), millions of individual investors -- and their fund managers -- will begin shoveling money into the stock ahead of the FDA's announcement.

Quite frankly, there is no calculating how high the stock will go.

Before long, heart attack patients across the world will be demanding this medical treatment. And that will spark interest in the stock by investors all over the globe.

That's why I'm contacting you now.

Well before the FDA even gives its final approval, you can make a windfall by investing in this stock today.

Although the FDA announcement has not been made yet, I believe the stock will rally in anticipation of this

"[On your recommendations, I've made] \$9,618.55, or 48.01%; \$2877.3, or 75.70%; \$3693.01, or 35.49%"

A.L., VPI reader

announcement over the next few months. I've been around long enough to tell you that the pure "buzz" about this company's drug could be enough to propel the shares 465% higher.

Since a successful Phase III trial would yield this company a billion-dollar pill overnight, Wall Street will most likely get ahead of itself and place a premium on these shares before the FDA even gives its decision.

Right now, this company has a market cap of \$508 million. When Wall Street learns that this company could soon have a billion-dollar pill, it won't take long before the market cap hits \$1 billion. If shares trade at 8 times earnings, it could have an \$8 billion market cap...more than enough to quadruple your money.

I can't remember when a biotech company stood to make you 465% no matter if its drug was approved by the FDA or not. But that's the situation you have right now. It's virtually a no-lose deal.

That's why one physician-turned-stock-picker is buying shares right now...and why you should join him.

Big Pharma Is in Big Trouble

In a recent *Barons* issue, a roundtable of doctors reviewed seven medical breakthroughs that are likely to save lives and revive certain drug companies.

Although most of the article featured the standard names like Johnson & Johnson, Eli Lilly and Amgen, one

"I stand in awe of the way Jim Davidson surges forward... a sort of Paul Revere of the 21st century."

Margaret Finn, VPI reader

forward-thinking physician (who attended Harvard Medical School before ending up at a leading hedge fund company) confirmed what I know about this company.

"There are over 12 million Americans diagnosed with atherosclerosis, and cardiovascular disease remains the #1 killer in the U.S. [If this] drug proves safe, sales could readily surpass \$1 billion..."- Barron's

Not only could this company introduce a new billion-dollar drug on the market very soon, but Big Pharma also isn't prepared to introduce any competing drugs.

Why?

Because poor lab productivity is killing almost every large drug company. New drug development is at record-lows...and Wall Street is starting to take notice.

GlaxoSmithKline is a prime example of this slow development. When the company was created in 2000, Dr. Jean-Pierre Garnier, their chief executive, said, *"We will be the kings of science and innovation."* Since then, the company has introduced just three new medicines (only one of which it discovered).

This prompted *The New York Times* to run an article titled "Where Are All the New Drugs?"

The article pointed out that introduction of new drugs plummeted from a high of 53 in 1996 to just 17 last year...despite a near doubling in annual research spending to \$32 billion.

Since today's new drugs aren't coming from the big companies, small companies like this one stand to introduce the newest medical advances.

According to Myhrvold, the former top scientist at Microsoft I mentioned earlier, ***"If you look at the pipeline of drugs in clinical trials, way more of them were made by the little companies than the big guys."***

Big Pharma knows they're falling behind. So in an effort to kick start new drug discoveries, the \$400 billion worldwide pharmaceutical industry has rapidly consolidated.

But that's not working either...

Studies of drug industry mergers have found that the combined companies generally **lose** market share and shareholder value. "Mergers may be harming the industry's long-term ability to innovate," said Ken Getz, CEO of CenterWatch, which tracks clinical trials. You see, the bureaucratic tasks of combining companies can become the sole chore of many top scientists during a merger at the expense of progressing research projects. The result? Organizational confusion, shifting priorities, delays...

It's clear that the newest advances will come from smaller companies, and this one is the most promising of the group. But I'm not the only one who agrees.

On Wall Street, the stock is up 127% over the last 52 weeks. But in the following months leading to FDA approval, it's going much, much higher. Before I tell you the name of this stock and others like it -- and how to buy them -- allow me to introduce myself.

Why Early Investors Can Make a Fortune

My name is James Davidson. I'm the editor of ***Vantage Point Investment Advisory*** - a groundbreaking publication dedicated to finding opportunities that could return \$100 for every \$1 you invest. In fact, I've devoted much of my career to growing my own portfolio... and the portfolios of a select group of readers... exponentially. I've been doing this a long time.

"Thanks to Vantage Point, I'm \$7,500 New Zealand richer over the 25 days I've been buying stock."

Alan Lunt, VPI reader

In my newsletter, I search for companies bold enough to think that the world might be ready to take a giant leap again and believe that innovative technology can still put serious distance between a leader and the rest of the pack.

The company you just learned about tops my list...

Let me state up front that I am NOT a stockbroker or an investment banker. I got my start in 1970 as an assistant to a billionaire venture capitalist. I later founded my first company with an investment of \$10,000. That company now makes as much as \$5 million a year.

Since then, I've gone on to start several other successful businesses. Now I sit on the board of 20 or so technology companies. In fact, I was recently invited to sit on Merrill Lynch's technology advisory board.

You can see I am not one of those editors with no real-world investing experience. I've done and seen it all. I know exactly how to grow a successful company. And I especially know how to spot one.

Please forgive me if this sounds arrogant, but unlike other editors, I'm not searching for the "right" way to invest. I know the right way. And it has helped me acquire an eight-figure net worth.

My \$10 Million Secret (This Is the Only Way to Become Truly Wealthy)

My friends and I trade large blocks of shares. Sometimes we buy and sell whole companies. But it wasn't always that way.

I started out just like most people, buying 100 shares at a time. Investing a couple of thousand dollars at a time. But I saw early on that the way to true wealth was by finding "accelerated returns." And this lesson was driven home time and time again when I served as an assistant to a billionaire venture capitalist.

After helping my employer make tens of millions of dollars, I struck out on my own. I founded my first company with an investment of just \$10,000. That company now makes profits of as much as \$5 million in a single year.

How to Turn \$10,000 Into \$1 Million

by James Dale Davidson
Multi-Millionaire Investor

I want to introduce you to a style of investing that will be like no other you have ever learned... a strategy that shows you how to pick the handful of stocks with the potential to payoff at 100-to-1. That way, a modest \$5,000 investment could turn into \$500,000.

This is how some of the wealthiest people in the world got rich. It's how I became rich as well. In fact, this simple approach has enabled me to make 100 times my money... *10 times over*.

I tell you this not to boast, but only so you understand that I'm not just talking theory. I'm telling you what worked for me. And I believe it's the best way to make real wealth today. In a minute, I'll tell you about

I did it again when some friends and I paid \$1,000 cash to take over a \$300 million company on the verge of bankruptcy. Less than a year later, we had increased the company's net worth by \$5 million and sold our share for \$1 million -- making 1,000 times our money.

Today, I often trade in blocks of hundreds of thousands of shares. But again, I tell you this simply to show you that if you spot the same levels of opportunities, you can do the same thing. And that's why I'm writing you today -- to show you how to do just that.

You will never read about Johnson & Johnson, Proctor & Gamble, or General Electric in my publication. If that's what you're looking for, this service isn't for you.

You'll only learn about the select group of young and mostly unnoticed companies that have the power to change the way you and I live -- the way the computer

several breakthrough companies that are very similar to the ones that helped me make my fortune. They could help you make yours.

Throughout my life, I've made a close study of how people became rich in America, from the 17th century onward. In the early days, land ownership was the key to wealth. But from the middle of the 19th century on, most people who became really rich were investors in new technologies that transformed the economy.

Investors like Johns Hopkins and Andrew Carnegie made huge fortunes by backing railroads and steel, before everyone else recognized their importance. So when I tell you to beware of conventional thinking, I'm not just giving you an offhand opinion. I'm sharing my experience with you -- experience that has spanned many years and all types of markets.

And when I tell you there have never been more opportunities to multiply your wealth than there are today, it's because I firmly believe it. I'm not sitting around on my money. I'm invested in many of the same companies I am recommending to you...and I'm looking to increase my wealth 10 times over in the next few years.

did in the 1980s or the Internet did in the 1990s and the way this atherosclerosis pill could in the early 2000s.

These companies are on the verge of explosive growth... and a small investment in any one of them could turn thousands into millions. I'm not looking for a 5%, 10% or even 25% growth rate. I want the company that will double, triple, quadruple or more in less than 12 months. As my readers know, I consistently find them.

You see, I put my money where my mouth is. For reasons I'll explain below, my thorough investigation of these opportunities convinces me that each is on the verge of explosive growth. Everything I know goes into my *Vantage Point Investment Advisory*. Today I'm inviting you to join me. But you'll need to leave the investing crowd behind. You have to find an independent perspective -- what I call a 'vantage point' -- that lets you see far beyond conventional investing 'wisdom.'

Join today, and you'll take that critical first step toward your newfound key to success... Subscribe below now.

Today, I'm inviting you to join me. But you'll have to leave the investing crowd behind. You have to have an independent perspective -- what I call a "vantage point" -- that lets you see beyond conventional investing "wisdom."

A History of Superior Profits

As I said, I've been at this a long time. I started publishing a bulletin for investors in 1984. And over the years, I've helped my readers protect themselves and see huge gains time and time again.

- In 1989, when the Nikkei Dow was at 39,000, I predicted an imminent plunge and was right on the money. In 1992 my readers saw over **300%** on the crash of the Japanese stock market...

- In 1996, we saw **163%** gains with Seven Seas Petroleum and **491%** on crude oil futures...with conservative minimum margins.
- We nearly **tripled our money** on AMDL, developers of a new technology for the monitoring and early detection of cancer...
- By foreseeing that tobacco companies then-President Bill Clinton beat up would bounce back, we saw **405%** on Philip Morris...
- We gained more than **100%** on MultiCorp, a company with perhaps the best available software for setting and manipulating character languages like Chinese, Japanese and Korean on standard PC's...
- In 1997 we saw a gain of **105%** on Mediconsult Ltd...
- Our money more than doubled again with **142%** on Oproeru Resources...

My recent picks have done even better...

\$10,000 in 3 Trades Grew into \$80,500 ... in an Average of Five Months (That's an Annualized Gain of 401%!)

ICOS Pharmaceuticals (ICOS: Nasdaq) is a good example of how getting in on a major lifestyle trend early enough can make you a fortune.

When I recommended ICOS in March of 2003, I knew that VIAGRA single-handedly helped Pfizer's stock price shoot up 57% in a few months.

Although VIAGRA had the market cornered early on, I discovered ICOS had a new breed of erectile dysfunction drug poised to hit the market that could relegate Viagra to second-tier status.

This new drug, called Cialis, tested better than VIAGRA in effectiveness and ease of use. Unlike VIAGRA, which lasts two to four hours and must be taken two hours after eating, Cialis only takes 10 minutes and lasts for a couple of days. (It is casually dubbed "le weekend" in Europe).

Cialis, which was approved by the FDA November 21st, stands to capture \$2 billion of Viagra's market! So I recommended ICOS at \$18.28 a share, and it quickly shot up to over \$47 for a 157% gain in seven months.



79% Quick Gains off New Age Aerospace Company

The same month I recommended ICOS, I also recommended **Orbital Sciences Corp. (ORB: NYSE)**, a groundbreaking company that's a leading developer of rockets that launch satellites into space, test our

defense systems, and take out enemy vehicles.

Because of our ongoing tensions with the Middle East and North Korea, I knew that demand for these types of rockets would drastically increase. And I was right.

The U.S. Air Force contracted with Orbital for \$475 million, which helped put Orbital's quarter-over-quarter sales growth at 33% (compared to the industry average of 2.2%). For under \$6 a share, it looked like a bargain, so I put out a buy recommendation on ORB.

The chart below tells the story...



266% and More Off the Wi-Fi Revolution...So Far

You probably already heard the buzz about Wi-Fi (wireless fidelity), a high-speed wireless network that connects computers to networks and then to the Internet...all wirelessly. Already, "hot spots" that provide a wireless access to the Internet are cropping up at airports, commercial centers and your local Starbucks. Soon every laptop computer sold will be equipped with Wi-Fi compatible hardware. In fact, this market is expected to grow 70% in 2004.

This past summer I identified a "basket" of promising Wi-Fi stocks for my readers to get in early on this life-changing technology. **Semotus Systems (DLK: Nasdaq)** was one. My timing was impeccable. We bought in for just \$0.38 in July and within one month, the stock had soared to \$1.39 -- a **266% gain**. We sold half and are riding on +86% on the rest of our position.



Those three trades in ICOS, Orbital and Semotus alone would have provided you an annualized gain of 401%! In other words, an investment of \$10,000 in each could turn into \$150,300 over the course of a year.

And there have been many more gains in the last six months...

- Just last month I recommended that readers take profits on part of their holding of an exciting junior gold company. They could have racked up gains of **131% and 144%**. We're up **198%** on the rest of our shares, and holding on for more!
- Another of our Wi-Fi picks was closed out at **40%** last summer.
- Yet another stock in our Wi-Fi basket is **up 111%**, as I write this.
- Our Asian index fund is showing gains of **29%**.
- Our purchase of an exciting biotech has advanced **30%**.

Now, don't get me wrong...

I don't begin to claim that *every* exciting emerging company will multiply your money like the examples I've just cited. But because, as you've seen, the potential is so HUGE for our companies that do become winners, it doesn't really matter if, along the way, a couple of our recommendations fall by the wayside.

I'm not just looking for technology companies to invest in. I really don't care what the business is...as long as you get in on the birth of a new discovery. The object is to recognize a groundbreaking idea and invest early for maximum gains.

If you do, you can turn a small sum of money into a very large one in months, weeks, even days. I've done it hundreds of times myself. And so have my readers, who had the opportunity to make...

- **617%** in profits when England devalued its currency
- **354%** on a leading Canadian manufacturer of gambling equipment
- **178%** on a company with the technology to detect cancer in the early stages
- **405%** on tobacco companies that were beat up by President Bill Clinton
- **140%** on Seven Seas Petroleum.

Everything I know goes into ***Vantage Point Investment Advisory***. Each month I give you a 12-page report filled with new investment opportunities geared to grow your wealth two, three or fourfold in less than 12 months.

I know what you're thinking: This is going to cost me a fortune. But it'll cost far less than you could possibly imagine. I've already made my millions, so I don't need to charge you thousands of dollars to receive my advice. My objective is to help you grow your money -- not break your bank.

For about 80 cents a day (\$295 a year) I'll send you 12 monthly reports -- each one with groundbreaking opportunities to grow your money quickly. That's a 50% discount off the cover price.

If you decide to join me for two years, it'll only cost you 68 cents or \$495. You won't find a better deal anywhere for the kind of information I provide.

As soon as you order, I'll rush you a copy of my new Fortune-Maker investor briefing report **"The \$14.5 Billion-Dollar Pill That Could Save Your Life... and Make You Rich."** This special write-up details everything you need to know about my top pick...the one company that stands to steal \$14.5 billion in sales from Merck and Pfizer.

Remember, it's only a matter of time before national media and Wall Street realize this incredible opportunity. When that happens, millions of investors -- and their fund managers -- will be shoveling money into this stock, which I calculate would push the shares 465% higher over the next few months.

The gains you could make off this small health care company can be life changing. Plus, there's something else I'd like to send you...

My recent picks have so much potential that I've written six other investor briefings to bring you up to speed on these incredible opportunities.

You'll learn about six of my most promising stocks on the market. Collectively, they've already gained an average of 28% returns... so far. The reason I'm telling you about them is because I feel they're still going much, much higher. Either way, you'll get all seven of my **Fortune-Maker Investor Briefings** -- FREE:

- **Fortune-Maker #1:** The \$14.5 Billion Pill That Could Save Your Life... and Make You Rich
- **Fortune-Maker #2:** The Richest Gold Strike of the Last 30 Years
- **Fortune-Maker #3:** Every Investor's Dream for a Cancer Cure
- **Fortune-Maker #4:** Growing New Blood Vessels in the Heart
- **Fortune-Maker #5:** 1,000% Potential Profit in Medical Devices
- **Fortune-Maker #6:** From Parenting to Warfare, Cenuco Eyes the Future of Surveillance
- **Fortune-Maker #7:** Miracle Cures From Groundbreaking Science

This Offer Will Not Be Repeated -- Act Now or Miss It

Before you make your decision, please understand that my investing approach is not for everyone. You've got to be willing to put your money down and ride it out. I usually don't use the stop-losses because experience has shown that you make the most money when you follow my plan and stick to it.

Now, that doesn't mean that I'll never say to unload an unprofitable position. That would be foolish. But it does mean that I recommend riding out the rough spots. Huge returns only come from brave actions. Investors who run for cover at the first sign of trouble usually aren't there for the glory days.

But if you're that special investor who understands the tremendous economic forces behind certain companies that can turn \$25,000 into millions, then I'd like to invite you to claim your spot in my group.

Click the "Subscribe Now" button below to activate your membership, and I'll e-mail you all seven of my new report as soon as your payment is processed. It's all part of the special bonus you'll receive when you sign up for a one- or two-year membership to *Vantage Point Investment Advisory*.

Remember, if you're still hesitant, I'll offer you a special three-month trial subscription for just \$75. We'll bill your credit card \$75 every three months until you tell us to stop.

That way, you can get all the details on these stocks without having to commit to a one- or two-year subscription. If for any reason you are not

100% satisfied with *Vantage Point Investment Advisory*, let me know within 30 days and I'll refund ALL of your money back. And you can even keep all seven investor briefings for your trouble.

After that, I'll give you a prorated refund on all the remaining time of your subscription. It's a risk-free opportunity to become wealthy.

This is an amazing time to be an investor. There are more groundbreaking opportunities than ever before. You just have to know where to look. And I do.

I hope you will join me as a subscriber to *Vantage Point Investment Advisory*. I sincerely believe that there has never been a better time to grow rich. The technology that will shape our grandchildren's lives is being created right now. There are huge fortunes to be made.

"I really enjoy reading your very intellectual writings, and look forward to Vantage Point's arrival."

D.K., VPI reader

To sign up, simply click the **"Subscribe Now"** button below, and I will rush you all seven moneymaking reports to you.. I look forward to welcoming you into the *Vantage Point Investment Advisory* family.

With Warmest Regards,



James Dale Davidson
Editor, *Vantage Point Investment Advisory*

P.S. Don't let cynicism close your eyes to opportunity. Right now, you have a time-sensitive opportunity to buy shares of this \$14 stock before word leaks that it could steal \$14.5 billion in sales from two of the biggest pharmaceutical companies in the world. Pass this up today, and you'll kick yourself when this stock is trading for \$80 the next time you look it up.

Note: Vantage Point Investing is for bold investors seeking exponential returns. This investing strategy does not come without, at times, substantial risk. There is no guarantee that past performance will result in future profits.

A rectangular button with a blue gradient background and the text "Subscribe Now" in white, bold, sans-serif font.